PD-1 Combinations Explored in RCC

For High-Definition, Click

Several clinical studies will continue to investigation PD-1 inhibition in renal cell carcinoma, explains Brian I. Rini, MD. A large phase I study showed modest activity with nivolumab as a single-agent, with questions regarding a maximum tolerated dose still lingering.

The next wave of research will focus on combination strategies, specifically looking at nivolumab with a TKI, such as sunitinib or pazopanib. The most intriguing combination involves nivolumab and ipilimumab. This approach has shown promising activity for patients with melanoma, Rini notes.

View the video, to hear the discussion.